Multiply Labs
The Senior Robotics Test Engineer at Multiply Labs ensures the reliability and precision of robotics software used in automated cell therapy manufacturing systems. The role focuses on building and maintaining test infrastructure that validates robotic platforms before deployment in production environments. Operating at the intersection of robotics and biopharma, this position has a direct impact on the safety and effectiveness of life-saving therapies. The engineer will act as a key technical leader influencing system-level design and validation strategy.
Headquarters
San Francisco, California, United States
Company Size
11-50 employees
Founded
2016
Multiply Labs builds robotic biomanufacturing infrastructure powered by Physical AI to automate the production of advanced biological therapies, including cell therapies, gene therapies, antibodies, and RNA therapies. Their platform — comprising autonomous robotic clusters, fully automated unit operations, and integrated GMP-compliant software — enables biopharma partners to scale throughput, reduce costs, and eliminate contamination risks associated with manual processes. The company serves life-science organizations seeking to modernize their manufacturing stack for the next generation of complex biological drugs.
AI’s Next Revolution: Multiply Labs Is Scaling Robotics-Driven Cell Therapy Biomanufacturing Labs
Jan 12, 2026
Multiply Labs Announces New Collaboration to Automate Cell Therapy Manufacturing with Robotics
1 month ago
Multiply Labs partners with AstraZeneca to automate cell therapy manufacturing
1 month ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Multiply Labs.
Multiply Labs didn’t post a salary, so this is our estimate from similar listings.
Multiply Labs’ biomanufacturing robot to “slash cell therapy costs”
Sep 5, 2025